Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $125,933.76 in Stock

Key Points

• Andrew Fisher, General Counsel of Verona Pharma PLC, sold 9,584 shares at an average price of $13.14, decreasing his holdings by 2.24% to 417,903 shares valued at approximately $5.49 million.
• Verona Pharma shares have recently seen a 0.1% decline, trading at $105.40, with 861,362 shares changing hands and major institutional investors owning 85.88% of the stock.
• Multiple research analysts have downgraded Verona Pharma from a "strong buy" to a "hold" rating, resulting in a consensus rating of "Hold" with an average target price of $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) General Counsel Andrew Fisher sold 9,584 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $125,933.76. Following the completion of the transaction, the general counsel directly owned 417,903 shares of the company's stock, valued at approximately $5,491,245.42. The trade was a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Fisher also recently made the following trade(s):

• On Monday, June 16th, Andrew Fisher sold 80,000 shares of Verona Pharma PLC American Depositary Share stock. The shares were sold at an average price of $11.53, for a total value of $922,400.00.

Verona Pharma PLC American Depositary Share Trading Down 0.1%

Shares of Verona Pharma PLC American Depositary Share stock traded down $0.12 on Friday, reaching $105.28. 610,545 shares of the company's stock were exchanged, compared to its average volume of 4,298,595. The company has a market capitalization of $8.96 billion, a P/E ratio of -106.34 and a beta of 0.12. Verona Pharma PLC American Depositary Share has a 52 week low of $21.56 and a 52 week high of $105.50. The company has a debt-to-equity ratio of 0.87, a quick ratio of 8.73 and a current ratio of 10.71. The firm's 50-day moving average is $97.20 and its two-hundred day moving average is $75.53.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. The business had revenue of $103.14 million during the quarter, compared to analysts' expectations of $90.41 million. Sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Institutional Trading of Verona Pharma PLC American Depositary Share

Large investors have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $225,000. LPL Financial LLC increased its holdings in shares of Verona Pharma PLC American Depositary Share by 108.1% during the fourth quarter. LPL Financial LLC now owns 30,033 shares of the company's stock valued at $1,395,000 after acquiring an additional 15,598 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Verona Pharma PLC American Depositary Share by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 62,741 shares of the company's stock worth $2,914,000 after purchasing an additional 660 shares during the period. Trexquant Investment LP bought a new position in shares of Verona Pharma PLC American Depositary Share in the 4th quarter worth $1,447,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Verona Pharma PLC American Depositary Share by 27.2% in the 4th quarter. Wells Fargo & Company MN now owns 67,126 shares of the company's stock worth $3,117,000 after purchasing an additional 14,362 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on VRNA. Truist Financial downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Wolfe Research lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Cantor Fitzgerald upped their price target on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Cowen cut Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Finally, TD Cowen lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Eleven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.